Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CRIS, Curis (formerly CBMI) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (384)	7/18/2001 10:51:34 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 668

From the PR, for the books here on SI: Ivan Lieberburg, Ph.D., M.D., Elan's Chief Scientific and Medical Officer stated that, ``Elan's partnering strategy gives us the opportunity to leverage very important technology with leaders in their respective fields. I am particularly excited about entering into this important collaboration with Curis. Curis is clearly the world leader in Hedgehog technology, and there is now growing evidence that Hedgehog agonists could have broad reaching applications in a variety of neurological disorders that are extremely important to Elan, including Parkinson's disease, neuropathy, pain, multiple sclerosis and Alzheimer's disease.'' ``The business venture with Elan demonstrates the value of Curis' strong position in the exploitation of developmental pathways in tissue regeneration,'' said Dr. Doros Platika, M.D., President and Chief Executive Officer of Curis. ``We have identified growth factors and small molecules that have broad applications in many disease areas. This joint venture structure allows Curis to secure the resources for the development of its extensive pipeline while at the same time allowing it to retain a significant portion of the value creation.'' Jim